Ferring Pharmaceuticals, Inc.
Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)
- Conditions
- Crohn's Disease
- Interventions
- Drug: CPSI-2364 or placebo
- First Posted Date
- 2009-07-31
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT00950105
- Locations
- 🇺🇸
Quintiles, Overland Park, Kansas, United States
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
- Conditions
- Lower Urinary Tract Symptoms (LUTS)
- Interventions
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 404
- Registration Number
- NCT00947882
- Locations
- 🇧🇪
UZ Brussel, Brussels, Belgium
🇨🇦Dr Steinhoff Clinical Research, Victoria, British Columbia, Canada
🇨🇿Slezska nemocnice, prospevkova organizace, Urologicke oddeleni, Opava, Czech Republic
A Trial of Degarelix in Patients With Prostate Cancer
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 859
- Registration Number
- NCT00946920
- Locations
- 🇺🇸
Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸Palm Beach Urology Associates, PA, Wellington, Florida, United States
🇧🇪UZ Gent, Gent, Belgium
Effectiveness and Safety of Firmagon®
- Conditions
- Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma
- Interventions
- Other: Firmagon given by prescription according to SPC
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 676
- Registration Number
- NCT00930319
- Locations
- 🇩🇪
Investigational Site, Hohenzollerndamm 47a, Berlin, Germany
🇩🇪Investigational Site, Albert-Einstein-Straße 2, Berlin, Germany
🇩🇪Investigational Site, Reilstraße 129 a, Halle, Germany
A Study of Degarelix in Patients With Prostate Cancer
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 409
- Registration Number
- NCT00928434
- Locations
- 🇺🇸
Southeastern Urology Center, PA, Tallahassee, Florida, United States
🇺🇸Chesapeake Urology Associates, Baltimore, Maryland, United States
🇺🇸Urology Associates Research, Englewood, Colorado, United States
Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT00925938
- Locations
- 🇺🇸
Lyndhurst Gynecologic Associates, Winston-Salem, North Carolina, United States
🇺🇸Precision Trials, Phoenix, Arizona, United States
Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 138
- Registration Number
- NCT00902265
- Locations
- 🇩🇪
Investigational Site - Kurfürstendamm 33, Berlin, Germany
🇩🇪Investigational Site - Marburger Straße 12/13, Berlin, Germany
🇩🇪Investigational Site - Mehrower Allee 22, Berlin, Germany
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 182
- Registration Number
- NCT00884273
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Ospedali riuniti, Ancona, Italy
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
🇫🇮KYS/kirurgian klin (Kuopio), Kuopio, Finland
A Study of Zomacton in Children With Growth Hormone Deficiency
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2012-07-17
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 165
- Registration Number
- NCT00884000
- Locations
- 🇭🇺
University of Szeged, Szeged, Hungary
🇭🇺Petz Country Teaching Hospital, Gyor, Hungary
🇮🇳TOTALL Diabetes Hormone Institute, Indore, India
MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer
- Conditions
- Infertility
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 749
- Registration Number
- NCT00884221
- Locations
- 🇪🇸
IU Dexeus, Barcelona, Spain
🇪🇸IVI Valencia, Valencia, Spain
🇪🇸GINEFIV, Madrid, Madrid, Spain